CG Oncology Analyst Price Targets - Benzinga

CG Oncology Inc

CGONNASDAQ

Trade with Public

Trade with Public

$74.67

0.340.46%

Last update: Sep 4, 4:00 PM

$74.67

0.340.46%

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

CG Oncology Analyst Price Targets

Wall Street analyst price targets and consensus rating for CG Oncology (CGON).

Price Target Range — 11 Quarters

Analyst Consensus — 16 Analysts

15Buy

1Hold

Consensus RatingBuy# Analysts16Avg. Consensus PT$72Upside to Avg. PT-3.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	RBC Capital	Leonid Timashev	PT Cut	Outperform	$81→$79
Aug 7, 2026	Piper Sandler	Kelsey Goodwin	PT Raise	Overweight	$82→$85
Aug 7, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$82→$85
May 19, 2026	Wolfe Research	Kalpit Patel	Initiate	Peer Perform	—
May 18, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$100
May 14, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$77→$82
May 11, 2026	JP Morgan	Brian Cheng	PT Raise	Overweight	$91→$96
May 11, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$79→$81
May 11, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$75→$77
May 11, 2026	Wedbush	Yun Zhong	PT Raise	Outperform	$77→$80
Apr 27, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$73→$79
Apr 17, 2026	JP Morgan	Brian Cheng	PT Raise	Overweight	$65→$91
Apr 7, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Raise	Buy	$80→$100
Feb 27, 2026	HC Wainwright & Co.	Andres Y. Maldonado	PT Raise	Buy	$75→$80
Feb 10, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$66→$75
Jan 21, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$61→$73
Jan 16, 2026	Piper Sandler	Kelsey Goodwin	PT Raise	Overweight	$55→$70
Jan 12, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$62→$66
Dec 11, 2025	Wedbush	Robert Driscoll	Initiate	Outperform	$70
Nov 24, 2025	Truist Securities	Gregory Renza	Initiate	Buy	$62

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79

RBC Capital analyst Leonid Timashev maintains CG Oncology (NASDAQ:CGON) with a Outperform and lowers the price target from $81 to $79.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85

Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:CGON) with a Overweight and raises the price target from $82 to $85.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85

Truist Securities analyst Gregory Renza maintains CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $82 to $85.

Benzinga Newsdesk

PRO
Wolfe Research Initiates Coverage On CG Oncology with Peer Perform Rating

Wolfe Research analyst Kalpit Patel initiates coverage on CG Oncology (NASDAQ:CGON) with a Peer Perform rating.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CG Oncology, Maintains $100 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates CG Oncology (NASDAQ:CGON) with a Buy and maintains $100 price target.

Benzinga Newsdesk

PRO
Truist Securities Reiterates Buy on CG Oncology, Raises Price Target to $82

Truist Securities analyst Gregory Renza reiterates CG Oncology (NASDAQ:CGON) with a Buy and raises the price target from $77 to $82.

Benzinga Newsdesk